Defendant Name: MedQuist Inc.

Defendant Type: Public Company

Document Reference: court_doc2_09-cv-02297

Document Details

Legal Case Name SEC v. MedQuist Inc.
Document Name Final Judgment as to Defendant MedQuist Inc.
Document Date 13-Mar-2009
Document Format Civil Proceeding
Case Number 09-cv-02297
Federal District Court New York, Southern District of New York
Allegation Type Issuer Reporting and Disclosure
Document Summary On March 13, 2009, the Court issued a final judgment against Defendant MedQuist Inc. The Court stated: "The Securities and Exchange Commission . . . and Defendant MedQuist Inc. . . . consented to the Court's jurisdiction over Defendant and the subject matter of this action; consented to entry of this Final Judgment without admitting or denying the allegations of the Complaint (except as to jurisdiction); waived findings of fact and conclusions of law; and waived any right to appeal from this Final Judgment."

Disgorgement & Penalty Information

Resolutions
Enjoinment

Related Documents:

comp20949-medquist 12-Mar-2009 Complaint
Complaint
On March 12, 2009, the SEC filed a complaint against MedQuist Inc. The Commission stated "From 1999 until 2004, Defendant ("MedQuist" or ''the Company"), a New Jersey-based medical transcription company, claimed in SEC filings, press releases and earnings calls that the Company's strong financial performance was due to its disciplined and conservative business practices, while at the same time it was systematically and secretly inflating customer bills to increase revenues and profit margins."
LR-20949A 12-Mar-2009 Litigation Release
SEC Charges MedQuist Inc. and Former Senior Executives with Securities Fraud
The SEC stated that: "[It] filed a settled civil injunctive action against MedQuist Inc., a medical transcription company based in New Jersey, charging it with securities fraud and other violations of the federal securities laws. The Commission's complaint alleges that, from 1999 to 2004, MedQuist claimed in SEC filings, press releases and earnings calls that the Company's strong financial performance was due to its disciplined and conservative business practices, while at the same time it was systematically and secretly inflating customer bills to increase revenues and profit margins. Without admitting or denying the allegations, MedQuist agreed to be permanently enjoined from violating the antifraud, reporting, books and records, and internal controls provisions of the federal securities laws. "

Related Actions:

SEC v. Brian J. Kearns and Bruce J. Van Fossen
SEC v. John A. Donohoe, Jr.
SEC v. Brian J. Kearns and Bruce J. Van Fossen